- Home
- MIRA vs IBO Comparison
MIRA vs IBO Comparison
Compare MIRA & IBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- IBO
- Stock Information
- Founded
- MIRA 2020
- IBO 2018
- Country
- MIRA United States
- IBO United States
- Employees
- MIRA N/A
- IBO N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- IBO
- Sector
- MIRA Health Care
- IBO
- Exchange
- MIRA Nasdaq
- IBO NYSE
- Market Cap
- MIRA 20.5M
- IBO 22.1M
- IPO Year
- MIRA 2023
- IBO 2024
- Fundamental
- Price
- MIRA $0.95
- IBO $0.57
- Analyst Decision
- MIRA Strong Buy
- IBO
- Analyst Count
- MIRA 2
- IBO 0
- Target Price
- MIRA $14.00
- IBO N/A
- AVG Volume (30 Days)
- MIRA 360.9K
- IBO 10.7M
- Earning Date
- MIRA 05-12-2025
- IBO 05-23-2025
- Dividend Yield
- MIRA N/A
- IBO N/A
- EPS Growth
- MIRA N/A
- IBO N/A
- EPS
- MIRA N/A
- IBO N/A
- Revenue
- MIRA N/A
- IBO N/A
- Revenue This Year
- MIRA N/A
- IBO N/A
- Revenue Next Year
- MIRA N/A
- IBO N/A
- P/E Ratio
- MIRA N/A
- IBO N/A
- Revenue Growth
- MIRA N/A
- IBO N/A
- 52 Week Low
- MIRA $0.51
- IBO $0.51
- 52 Week High
- MIRA $5.01
- IBO $6.17
- Technical
- Relative Strength Index (RSI)
- MIRA 38.16
- IBO N/A
- Support Level
- MIRA $1.06
- IBO N/A
- Resistance Level
- MIRA $1.29
- IBO N/A
- Average True Range (ATR)
- MIRA 0.11
- IBO 0.00
- MACD
- MIRA -0.02
- IBO 0.00
- Stochastic Oscillator
- MIRA 4.74
- IBO 0.00
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.